High Fat Diet Attenuates Cholecystokinin-Induced cFos Activation of Prolactin-Releasing Peptide-Expressing A2 Noradrenergic Neurons in the Caudal Nucleus of the Solitary Tract.
CCK
PrRP
rat
satiety
Journal
Neuroscience
ISSN: 1873-7544
Titre abrégé: Neuroscience
Pays: United States
ID NLM: 7605074
Informations de publication
Date de publication:
01 11 2020
01 11 2020
Historique:
received:
09
04
2019
revised:
22
08
2019
accepted:
28
08
2019
pubmed:
14
9
2019
medline:
15
5
2021
entrez:
14
9
2019
Statut:
ppublish
Résumé
Cholecystokinin (CCK) released from the small intestine increases the activity of vagal afferents that relay satiety signals to the caudal nucleus of the solitary tract (cNTS). A caudal subset of A2 noradrenergic neurons within the cNTS that express prolactin-releasing peptide (PrRP) have been proposed to mediate CCK-induced satiety. However, the ability of exogenous CCK to activate cFos expression by PrRP neurons has only been reported in rats and mice after a very high dose (i.e., 50 μg/kg BW) that also activates the hypothalamic-pituitary-adrenal stress axis. The present study examined the ability of a much lower CCK dose (1.0 µg/kg BW, i.p) to activate PrRP-positive neurons in the rat cNTS. We further examined whether maintenance of rats on high fat diet (HFD; 45% kcal from fat) alters CCK-induced activation of PrRP neurons, since HFD blunts the ability of CCK to suppress food intake. Rats maintained on HFD for 7 weeks consumed more kcal and gained more BW compared to rats maintained on Purina chow (13.5% kcal from fat). CCK-treated rats displayed increased numbers of cFos-positive cNTS neurons compared to non-injected and saline-injected controls, with no effect of diet. In chow-fed rats, a significantly larger proportion of PrRP neurons were activated after CCK treatment compared to controls; conversely, CCK did not increase PrRP neuronal activation in HFD-fed rats. Collectively, these results indicate that a relatively low dose of exogenous CCK is sufficient to activate PrRP neurons in chow-fed rats, and that this effect is blunted in rats maintained for several weeks on HFD.
Identifiants
pubmed: 31518655
pii: S0306-4522(19)30647-5
doi: 10.1016/j.neuroscience.2019.08.054
pmc: PMC7819360
mid: NIHMS1539481
pii:
doi:
Substances chimiques
Prolactin-Releasing Hormone
0
Cholecystokinin
9011-97-6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-121Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK100685
Pays : United States
Informations de copyright
Copyright © 2019 IBRO. Published by Elsevier Ltd. All rights reserved.
Références
Curr Opin Pharmacol. 2007 Dec;7(6):570-4
pubmed: 17954038
Regul Pept. 2000 Jan 29;86(1-3):83-8
pubmed: 10672906
Psychopharmacology (Berl). 2018 Aug;235(8):2287-2301
pubmed: 29796829
J Comp Neurol. 1995 Sep 18;360(2):246-56
pubmed: 8522645
Science. 1988 Jun 3;240(4857):1328-31
pubmed: 3131879
J Neuroendocrinol. 2000 Feb;12(2):131-40
pubmed: 10718908
Endocrinology. 1999 May;140(5):2326-33
pubmed: 10218986
Int J Obes (Lond). 2009 Apr;33 Suppl 1:S11-5
pubmed: 19363500
Cell Metab. 2014 Oct 7;20(4):639-49
pubmed: 25176149
Endocrinology. 2001 May;142(5):2032-8
pubmed: 11316770
Endocrinology. 2002 Feb;143(2):368-74
pubmed: 11796488
J Comp Neurol. 1993 Dec 22;338(4):475-90
pubmed: 8132858
Eur J Neurosci. 2002 Dec;16(11):2186-98
pubmed: 12473086
Physiol Behav. 2013 Sep 10;121:35-42
pubmed: 23391574
Am J Physiol. 1999 May;276(5):R1545-9
pubmed: 10233050
Am J Physiol. 1998 Jul;275(1):R262-8
pubmed: 9688987
Nature. 1998 May 21;393(6682):272-6
pubmed: 9607765
Physiol Behav. 2002 Dec;77(4-5):723-9
pubmed: 12527026
Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E898-903
pubmed: 19190260
Endocrinology. 1992 Apr;130(4):1764-74
pubmed: 1312423
Physiol Behav. 2014 Sep;136:47-54
pubmed: 24508750
J Histochem Cytochem. 1974 Dec;22(12):1077-83
pubmed: 4374474
J Mol Neurosci. 2004;22(1-2):93-103
pubmed: 14742914
Am J Physiol Regul Integr Comp Physiol. 2009 Nov;297(5):R1238-46
pubmed: 19726710
J Neuroendocrinol. 1991 Apr 1;3(2):205-13
pubmed: 19215523
J Clin Invest. 2008 Dec;118(12):4014-24
pubmed: 19033670
J Neurosci. 2003 Nov 5;23(31):10084-92
pubmed: 14602823
Annu Rev Neurosci. 1991;14:421-51
pubmed: 1903243
Physiol Behav. 2006 Nov 30;89(4):477-85
pubmed: 16872644
J Neurosci. 2015 Jul 29;35(30):10701-14
pubmed: 26224855
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Int J Obes (Lond). 2009 Apr;33 Suppl 1:S7-10
pubmed: 19363513
Endocrinology. 2006 Oct;147(10):4723-9
pubmed: 16794001
J Nutr. 2005 Aug;135(8):1953-9
pubmed: 16046722
Clin Exp Pharmacol Physiol. 2005 May-Jun;32(5-6):355-66
pubmed: 15854142
Peptides. 1998;19(8):1407-15
pubmed: 9809656
Neuroscience. 1995 May;66(2):403-12
pubmed: 7477881
Neurosci Biobehav Rev. 1996;20(1):155-61
pubmed: 8622822
Nutr Neurosci. 2019 May 22;:1-10
pubmed: 31116091
J Neuroendocrinol. 1992 Apr;4(2):149-52
pubmed: 21554590
Brain Res. 1999 Mar 20;822(1-2):276-9
pubmed: 10082910
Am J Physiol Regul Integr Comp Physiol. 2006 Jun;290(6):R1544-9
pubmed: 16384857
Cell Metab. 2012 Sep 5;16(3):296-309
pubmed: 22902836
Front Neurosci. 2013 Jan 21;6:199
pubmed: 23346044
J Neurosci. 2007 Nov 28;27(48):13292-302
pubmed: 18045923
Obes Res. 1993 May;1(3):173-8
pubmed: 16353351
Front Neuroendocrinol. 1993 Jul;14(3):173-213
pubmed: 8349003
Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R1005-10
pubmed: 14557233
Am J Physiol. 1997 Aug;273(2 Pt 2):R725-30
pubmed: 9277561
Neuroscience. 2003;121(3):771-8
pubmed: 14568035
Brain Res. 2010 Sep 2;1350:18-34
pubmed: 20353764
Peptides. 1986 Jan-Feb;7(1):155-9
pubmed: 3520509
PLoS One. 2012;7(3):e32967
pubmed: 22412960
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Endocrinology. 2002 Feb;143(2):360-7
pubmed: 11796487
J Comp Neurol. 2002 Mar 12;444(3):191-206
pubmed: 11840474
Trends Endocrinol Metab. 2010 May;21(5):287-93
pubmed: 20122847
Am J Physiol. 1997 Aug;273(2 Pt 2):R833-7
pubmed: 9277576